Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Amortization (2022 - 2024)

Historic Amortization for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q4 2024 value amounting to -$946.0 million.

  • Indivior Pharmaceuticals' Amortization rose 2756.51% to -$946.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$946.0 million, marking a year-over-year increase of 2756.51%. This contributed to the annual value of -$946.0 million for FY2024, which is 2756.51% up from last year.
  • As of Q4 2024, Indivior Pharmaceuticals' Amortization stood at -$946.0 million, which was up 2756.51% from -$962.0 million recorded in Q3 2024.
  • Indivior Pharmaceuticals' Amortization's 5-year high stood at $1.3 billion during Q4 2022, with a 5-year trough of -$1.3 billion in Q4 2023.
  • Its 3-year average for Amortization is -$496.6 million, with a median of -$954.0 million in 2024.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Amortization plummeted by 20373.31% in 2023, and later soared by 2756.51% in 2024.
  • Over the past 3 years, Indivior Pharmaceuticals' Amortization (Quarter) stood at $1.3 billion in 2022, then plummeted by 203.73% to -$1.3 billion in 2023, then rose by 27.57% to -$946.0 million in 2024.
  • Its Amortization was -$946.0 million in Q4 2024, compared to -$962.0 million in Q3 2024 and -$1.0 billion in Q2 2024.